Company
Science
Products & Pipeline
News
Careers
Investors

Locations
Contact

Locations
Contact

Search

Search BioMarin

Back to News Back to Stories

Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A

February 23, 2023

Related Stories

No related posts.

You’re leaving the BioMarin website.

Links to sites outside of this website are provided as a resource to the viewer. BioMarin accepts no responsibility for the content of linked sites.

Leave this website Close

Contact

Publication Data Request
Report an Adverse Event
Report a Product Complaint
Product Replacement Request
Submit a Medical Information Inquiry

Legal

Supply Chain Statement
Biomarin Data Privacy Center
Terms of Use
Cookie Settings

LinkedIn
X
Instagram
Facebook

© 2024 BioMarin. All rights reserved.